Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc announces new data presented at ASH annual meeting enhance understanding of PNH and aHUS to provide optimal care for patients with these life-threatening disorders


Sunday, 8 Dec 2013 11:24pm EST 

Alexion Pharmaceuticals Inc:Says that researchers presented data from clinical trials demonstrating the clinical benefits of chronic Soliris (eculizumab) treatment in patients with atypical hemolytic uremic syndrome (aHUS).Says new patient registry data providing further insight into optimal care for patients with paroxysmal nocturnal hemoglobinuria (PNH).Says a new, comprehensive study of key aHUS biomarkers indicating that, prior to initiation of Soliris treatment, aHUS patients have severe ongoing terminal complement activation and inflammation with increased thrombotic risk.Says the study further indicates that inhibition of terminal complement activation with Soliris should be sustained because loss of terminal complement inhibition could lead to potentially catastrophic clinical consequences.Says the results from the first prospective clinical trial in pediatric patients with aHUS, which confirm previous results from a retrospective pediatric study, and support the use of Soliris as first-line treatment for children with aHUS. 

Company Quote

188.15
-1.38 -0.73%
19 Dec 2014